NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 116 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.29 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,436 | -58.7% | 4,146 | 0.0% | 0.00% | – |
| Q2 2023 | $10,738 | -70.6% | 4,146 | -53.7% | 0.00% | -100.0% |
| Q1 2023 | $36,569 | -18.7% | 8,963 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $44,994 | -57.1% | 8,963 | +11.9% | 0.00% | -50.0% |
| Q3 2022 | $105,000 | +69.4% | 8,012 | +66.3% | 0.00% | +100.0% |
| Q2 2022 | $62,000 | +100.0% | 4,817 | +138.8% | 0.00% | – |
| Q1 2022 | $31,000 | -26.2% | 2,017 | +0.8% | 0.00% | -100.0% |
| Q3 2021 | $42,000 | +7.7% | 2,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $39,000 | -100.0% | 2,000 | -50.0% | 0.00% | 0.0% |
| Q1 2021 | $116,280,000 | – | 4,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |